Introduction
Irradiation is rarely an effective tool as the only component of treatment (primary or adjuvant) for gastrointestinal cancers. To achieve its maximum effectiveness, external beam irradiation (EBRT) is usually combined with both concomitant and maintenance chemotherapy. For squamous cancers of the esophagus and anus, improvements in disease control and survival (both), and organ preservation (anus) have been achieved with EBRT plus concomitant and maintenance 5-FU + cisplatin or 5-FU + mitomycin-C [ 1 -6] . For locally unresectable or locally recurrent adenocarcinomas of the GI tract, EBRT has been combined with 5-FU based regimens with resultant improvement in local control and survival (pancreas, gastric, large bowel ± bile duct) [7] [8] [9] [10] [11] . In an adjuvant setting, postoperative EBRT plus 5-FU based regimens have improved disease control and survival when compared with surgery alone (rectum, pancreas, ± stomach) or adjuvant EBRT control arms (rectum) [7, 11, 12] .
When upper gastrointestinal cancers, including biliary and pancreatic, are unresectable or residual disease exists after maximal resection, EBRT doses necessary to accomplish local control are 60 to 270 Gy which exceeds the radiation tolerance of some organs and structures in the abdomen (stomach, small intestine, and spinal cord can tolerate 45 to 50 Gy in 1.8 to 2.0 Gy fractions over 5 to 5'/2 weeks). If a portion of irradiation is given at the time of a surgical procedure, all or part of the dose-limiting structures may be excluded by operative mobilization or shielding or by use of variable energy electrons. In addition, the volume of the irradiation boost field is decreased by treating the tumor under direct vision, using appositional placement of lucite applicators to direct the electrons.
Pancreas cancer, adjuvant

Patterns of relapse, surgery alone
Minimal data exists on patterns of relapse after total resection of pancreatic cancer. In a series of 31 resected patients from Massachusetts General Hospital (MGH), 22 of 26 postoperative survivors died of disease, and reoperative or autopsy information was available in 13 [13] . The incidence of local regional relapse in the pancreatic bed or nodal regions was 50% (13 of 26) and liver metastases were also common. A separate analysis by University of Kansas investigators demonstrated similar local relapse rates (50%) after resection and a high incidence of both liver metastases (44%) and peritoneal seeding (31%) [14] .
Radical node dissections are being performed in some institutions in an attempt to decrease the rate of nodal relapse and thereby improve survival. However, because of anatomic constraints, it is difficult to perform a complete node dissection, and tumor bed resection margins will still be narrow in view of the postero-medial proximity of the portal vein and superior mesenteric vessels.
Adjuvant chemoirradiation results
In patients with resectable lesions, adjuvant chemoirradiation is usually indicated on the basis of patterns of relapse after surgery alone, the results of a prospective randomized trial from the Gastrointestinal Tumor Study Group (GITSG) [15] and single institution results from Mayo Clinic and Johns Hopkins. In the GITSG trial, patients were randomized to receive no further treatment (surgery alone control arm -22 patients) or EBRT plus 5-FU (40 Gy in 20 fractions of 2 Gy with a 6-week split course technique involving concomitant 5-FU 500 mg/m 2 days 1 to 3 of each EBRT sequence followed by maintenance weekly 5-FU for 2-years -23 patients). EBRT fields were designed to include the tumor bed as well as major nodal areas at risk. A survival advantage seen with the combined treatment resulted in nearly a doubling of median survival (20 versus 11 months), 2-year survival of 42% versus 15% and 5-year survival of 19% versus 5% (P=0.05). The GITSG subsequently treated 30 additional patients with combined modality EBRT plus 5-FU. Results in those 30 patients replicated and confirmed the improved survival seen in the randomized trial [16] . With the low doses of irradiation used in the GITSG trial (40 Gy in 6 weeks + 5-FU), the adjuvant treatment did not appear to have a significant impact on local control. The incidence of local recurrence was high in both the arms (33% and 45% of evaluable patients). In a Mayo Clinic series of 29 patients, higher doses of EBRT were combined with concomitant 5-FU with an apparent improvement in local control when compared with the GTSG data [17] . A four-field technique was used to deliver 45 Gy in 1.8 Gy fractions to a tumor bed nodal field and 50-54 Gy within a tumor bed boost field in a majority of patients who received adjuvant treatment after gross total resection. A doubling in median and long-term survival was seen with adjuvant chemoirradiation when compared with Mayo Clinic results achieved with surgery alone (no apparent changes in surgical techniques) ( Table 1 ). Local regional relapse was documented in only 2 of 28 patients (7%) who had a curative resection followed by adjuvant EBRT plus 5-FU.
In a recently published series from Johns Hopkins, adjuvant postoperative chemoirradiation improved disease control and survival when combined with 1990's era surgical resection [18] . After resection, patients were seen in a multidisciplinary clinic and given the option of adjuvant chemoirradiation versus no further treatment (surgery alone control -non-randomized). Both median and long-term survival appeared better with adjuvant treatment (median 13.5 vs 19.5 mo; 1-year 54 vs 80%, 2-year 30 vs 39% P = 0.0003).
Pancreas cancer, locally unresectable
EBRT ± chemotherapy
For locally unresectable pancreas cancer, the use of EBRT with concomitant ± maintenance chemotherapy results in a doubling in median survival (SR) when compared with surgical bypass or stents alone (3-6 months median SR versus 9-13 months) and an increase in 2-year SR from 0%-5% to 10%-20% [11] . However, both 5-year survival and local control are infrequent. With EBRT doses of 60-70 Gy, plus concomitant chemotherapy, local relapse was still documented in at least two-thirds of the patients in a series from Thomas Jefferson University (TJUH) ( Table 2 ) [21] .
Intraoperative irradiation ± EBRT
The combination of EBRT plus intraoperative electron irradiation (IOERT) or brachytherapy has resulted in an improvement in local control in IOERT series from MGH [22] and Mayo [23] and brachytherapy series from MGH [24] and TJUH [21] , but this has not resulted in an improvement in either median or long-term survival (Table  2 ). In the Mayo analysis, the local control rate at 1-year was 82% for EBRT plus IOERT ± 5-FU versus 48% for EBRT ± 5-FU; at 2-years it was 66% versus 20%, respectively (P = 0.0005) [23] . However, survival was equivalent (13.4 months median SR with IOERT versus 12.6 months without; 2-year SR 12% versus 16.5%). The equivalent survival was due to a high incidence of abdominal relapse in both treatment groups (20 of 37 IOERT patients, or 54% developed liver or peritoneal metastases versus 68 of 122 or 56% in non-IOERT patients). A high incidence of abdominal relapse has been found in other IOERT analyses including MGH [22] .
Brachytherapy plus EBRT has produced results similar to the IOERT plus EBRT data. Although local control was improved considerably with the addition of an Iodine 125 implant to EBRT ± chemotherapy at 78% versus 19% in a TJUH analysis, median survival was the same at 11.3 versus 12.4 months [21] .
Mayo Clinic investigators delivered the EBRT plus concomitant chemotherapy component of treatment before restaging, exploration and IOERT in a subsequent series of patients in an attempt to improve patient selection and survival [25] . In 27 patients who received EBRT plus 5-FU before IOERT, local control was achieved in 21 patients (78%) with actuarial rates of 86% and 68% at 1-and 2-years, respectively. Median survival was 14.9 months with this sequence and 2-and 5-year survival were respectively 27% and 7%. These findings were compared with results in 56 patients who had IORT before receiving the EBRT component of treatment at Mayo or elsewhere (median SR 10.5 months, 2-year SR 6%, P = 0.001). In an earlier analysis of 37 patients treated solely at Mayo with the latter sequence, median and 2-year survival were respectively 13.6 months and 12%. Although 2-year survival appeared to be improved with the altered sequence of preoperative EBRT + 5-FU followed by IORT, this was presumably due to altered patient selection as the relative rate of liver plus peritoneal relapse was the same (14 of 27 patients at risk or 52%).
Pancreas cancer: Future possibilities
Various pilot studies have been conducted in an attempt to decrease the incidence of liver/peritoneal failures by utilizing whole abdomen irradiation plus concomitant 5-FU or more aggressive chemotherapy regimens. To date, none of these approaches has been successful in altering survival treatment outcomes. For patients with locally advanced or metastatic disease, a four-drug combination was tested in a NCCTG/Mayo pilot study (infusion 5-FU, daily oral leucovorin, mitomycin C, and Persantine) on the basis of single institution response rates of 40%. The two-drug combination of protracted venous infusion 5-FU and oral leucovorin was combined with EBRT in a separate chemotherapy dose escalation pilot study (NCCTG/Mayo) for patients with locally unresectable lesions. Results with the four-drug regimen for metastatic disease were not as optimistic as found in the single institution setting with response rates of -25%. New single institution and group studies have been designed to test gemcitabine and cisplatin containing regimens for metastatic disease. The most aggressive pilot study combines both drugs with 5-FU during EBRT and for systemic management.
Mayo/NCCTG studies are evaluating gemcitabine plus cisplatin combinations; ECOG is evaluating 5-FU plus gemcitabine. Further improvements in disease control and survival may necessitate regional approaches for chemotherapy (intrahepatic chemotherapy, intraperitoneal monoclonal antibodies or p32) or may await developments in molecular level therapies.
Biliary tract cancers, adjuvant
Patterns of relapse -surgery ± adjuvant treatment
Local relapse in the tumor bed or regional nodes is common after "curative resection" for both gallbladder and extrahepatic bile duct cancers [20, 26] . With bile duct cancer, proximal and distal margins of resection are often narrow or microscopically positive as are radial or circumferential margins when lesions extend through the entire duct wall. Local relapse is a frequent cause of death. In an MGH series of 28 patients with curative resection for gallbladder or ductal lesions, locoregional relapse was the major mode of relapse occurring in 13 of the 25 postoperative survivors (52%) [26] . Initial tumor extension through the wall of the organ seemed to be the best predictor with locoregional relapse occurring in 4 of 11 patients (36%) with lesions confined to the bile duct wall and in 9 of 14 (64%) with lesions extending beyond the wall. Patterns of relapse were also analyzed in 41 MGH patients with resected ampullary carcinomas [27] . In 12 patients with low-risk pathologic features (limited to ampulla or duodenum, well or moderately differentiated, uninvolved margins and nodes), the 5-year actuarial local control and survival were 100% and 80%, respectively, with surgery alone. In 17 high-risk patients treated with surgery alone, those rates were 50% and 38%, respectively (p < 0.05) (high risk was defined as tumor invasion of pancreas, poorly differentiated lesions, involved nodes or margins). An additional 12 patients with high risk cancers received postoperative EBRT ± 5-FU.
Although adjuvant chemoirradiation appeared to improve 5-year local control and survival (83% vs 50% and 51% vs 38%, respectively), these differences were not statistically significant in view of small patient, numbers and distant relapse rates.
Biliary tract cancers, unresectable or residual As discussed previously, chemoirradiation appears to improve local control and survival of locally unresectable or residual biliary tract cancers when compared with single modality treatment [28] . Although treatment intensification with IOERT, brachytherapy or conformal EBRT appears to further enhance disease control and survival, local relapse still occurs in 40%-50% of patients and long-term survival is limited to 15%-20% of patients at risk. 
Adjuvant biliary
Although improved resectability and survival rates have been achieved with surgery alone in modem series, longterm survival is still limited to 40%-50%. Prospective trials of chemoirradiation should be performed that evaluate issues of sequencing (preoperative, postoperative) and treatment intensification.
Locally advanced biliary
In an attempt to improve survival and disease control for patients with locally advanced biliary tract malignancies, it would be appropriate to evaluate treatment combinations of the various modalities that appear to impact those endpoints. For lesions that are unresectable with standard or extended surgical procedures, these options include EBRT, simultaneous ± maintenance chemotherapy, a specialized irradiation boost with transcatheter iridium or IOERT ± an orthotopic liver transplant (OLT). Improved imaging techniques would be helpful in defining both surgical resectability and tumor/target volumes for EBRT (standard and 3-D conformal) and specialized boosts with IOERT, brachytherapy or 3-D coplanar or non-coplanar beams.
Increased utilization of EBRT with simultaneous and maintenance chemotherapy is indicated in view of results in single institution studies in patients with bile duct cancers [28] and randomized single institution and group trials in other GI sites (unresectable pancreas; unresected or residual gastric and large bowel; resected but high-risk rectal and pancreas ± gastric; unresected esophagus and anus) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . The use of protracted low-dose infusion 5-FU instead of bolus 5-FU during EBRT may be safer and more efficacious as it would be less apt to result in severe leukopenia in a stented patient who is at risk for tube-related sepsis. With regard to the use of IOERT versus brachytherapy or 3-D EBRT for a specialized boost, this is dependent on whether the patient is a potential candidate for resection. If the primary lesion appears to be surgically unresectable on the basis of imaging studies and the specialized irradiation boost can safely be given via the transcatheter or 3-D EBRT approach, these are more cost efficacious methods of delivery. If stomach or duodenum cannot be excluded from a brachytherapy or EBRT field, however, it may be reasonable to reoperate for the purpose of giving the boost with IOERT while displacing those structures. For patients in whom microscopic or gross residual disease remains after an attempt at resection, the addition of EBRT ± chemotherapy seems reasonable on the basis of bile duct analyses by the EORTC group and Weiss et al., and the use of IOERT (plus EBRT and resection) is supported by the excellent long-term results achieved in locally advanced gallbladder cancers in Tsukuba [28] . The availability of IOERT or high dose rate brachytherapy IORT (HDR-IORT) may allow delivery of a localized boost dose of irradiation after resection but before reconstruction as in the Tsukuba gallbladder and bile duct series by Todoroki et al. [28] (i.e., IOERT for positive radial or circumferential margins due to adherence to porta hepatis structures that could not be boosted with postoperative transcatheter iridium; HDR-IORT for microscopically positive ductal margins). It would be of interest to investigate sequencing issues in patients with potentially or borderline resectable lesions (give EBRT plus 5-FU before instead of after resection to alter implantability of cells that may be shed at the time of resection).
For patients who present with surgically unresectable or borderline resectable lesions, it would be reasonable to initiate treatment with preoperative EBRT plus protracted venous infusion 5-FU and plan to re-evaluate 3-4 weeks after completion of such for the option of attempted gross total resection ± a specialized IORT boost with IOERT or HDR IORT as previously discussed. This approach is supported by results in EBRT ± brachytherapy bile duct series from Heidelberg, Rotterdam, Lyon and Mayo Clinic which show a survival advantage for patients with resection vs no resection and the excellent 5-year results with resection plus IOERT and EBRT in locally advanced gallbladder and bile duct cancers demonstrated by Todoroki et al. in Tsukuba [28] . Both Mayo Clinic and the University of Pittsburgh are conducting pilot studies in which patients with proximal bile duct lesions are candidates for liver transplant following preoperative EBRT plus concomitant 5-FU ± brachytherapy (Mayo) for lesions which are unresectable by standard surgical criterion. In a Pittsburgh series of 61 patients, 23 patients had complete resection after preoperative EBRT and chemotherapy; 17 of 23 had a liver transplant) [29] . The altered sequencing of preoperative EBRT plus chemotherapy in this recent series [29] , instead of postoperative chemoirradiation as used in a prior series [30] , appeared to translate into improved long-term survival (median survival 2:60 vs 12 mo.; four-year survival 53.5 vs 22%) ( Table 3) . In an unpublished Mayo Clinic series, 16 patients received EBRT plus concomitant 5-FU and brachytherapy prior to staging laparotomy and 9 received a subsequent liver transplant. All nine are alive, disease-free with median follow-up of 24 months (range 7-60 months; 7 z 22 months).
